Published in Nucleic Acids Res on January 14, 2005
Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res (2006) 3.22
A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res (2009) 1.84
Chemical modification: the key to clinical application of RNA interference? J Clin Invest (2007) 1.81
Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J Am Soc Nephrol (2012) 1.70
Strand-specific 5'-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA (2007) 1.61
RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med (2009) 1.59
miR-21: an oncomir on strike in prostate cancer. Mol Cancer (2010) 1.54
Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res (2007) 1.53
Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA (2007) 1.46
Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med (2012) 1.35
The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther (2009) 1.35
The influence of locked nucleic acid residues on the thermodynamic properties of 2'-O-methyl RNA/RNA heteroduplexes. Nucleic Acids Res (2005) 1.35
Engineering RNA for targeted siRNA delivery and medical application. Adv Drug Deliv Rev (2010) 1.32
A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. Nucleic Acids Res (2010) 1.26
Fabrication of stable and RNase-resistant RNA nanoparticles active in gearing the nanomotors for viral DNA packaging. ACS Nano (2010) 1.21
Minimizing off-target effects by using diced siRNAs for RNA interference. J RNAi Gene Silencing (2006) 1.20
Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther (2012) 1.18
The emerging roles of microRNAs in CNS injuries. Nat Rev Neurol (2013) 1.18
Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs. Oligonucleotides (2008) 1.17
Effect of base modifications on structure, thermodynamic stability, and gene silencing activity of short interfering RNA. RNA (2007) 1.16
Stable RNA nanoparticles as potential new generation drugs for cancer therapy. Adv Drug Deliv Rev (2013) 1.15
Improvements in siRNA properties mediated by 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (FANA). Nucleic Acids Res (2006) 1.14
siRNA Versus miRNA as Therapeutics for Gene Silencing. Mol Ther Nucleic Acids (2015) 1.12
Sequence-non-specific effects of RNA interference triggers and microRNA regulators. Nucleic Acids Res (2009) 1.11
Analysis of acyclic nucleoside modifications in siRNAs finds sensitivity at position 1 that is restored by 5'-terminal phosphorylation both in vitro and in vivo. Nucleic Acids Res (2009) 1.10
MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity. Mol Biosyst (2006) 1.10
Light-activated RNA interference using double-stranded siRNA precursors modified using a remarkable regiospecificity of diazo-based photolabile groups. Nucleic Acids Res (2009) 1.04
Synergistic effects between analogs of DNA and RNA improve the potency of siRNA-mediated gene silencing. Nucleic Acids Res (2010) 1.03
2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun (2014) 1.03
Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA. Br J Pharmacol (2009) 1.01
siPools: highly complex but accurately defined siRNA pools eliminate off-target effects. Nucleic Acids Res (2014) 1.01
Insights into structure, dynamics and hydration of locked nucleic acid (LNA) strand-based duplexes from molecular dynamics simulations. Nucleic Acids Res (2008) 1.00
High potency silencing by single-stranded boranophosphate siRNA. Nucleic Acids Res (2006) 1.00
Optimized siRNA-PEG conjugates for extended blood circulation and reduced urine excretion in mice. Theranostics (2013) 0.97
Effect of chemical modifications on modulation of gene expression by duplex antigene RNAs that are complementary to non-coding transcripts at gene promoters. Nucleic Acids Res (2010) 0.97
Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering. Front Genet (2012) 0.95
A novel noncoding RNA processed by Drosha is restricted to nucleus in mouse. RNA (2008) 0.95
Duplex end breathing determines serum stability and intracellular potency of siRNA-Au NPs. Mol Pharm (2011) 0.93
The fascinating world of RNA interference. Int J Biol Sci (2009) 0.92
MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics. Cancer Med (2016) 0.89
RNA interference in mammalia cells by RNA-3'-PNA chimeras. Int J Mol Sci (2008) 0.89
The crystal structure of an 'All Locked' nucleic acid duplex. Nucleic Acids Res (2010) 0.87
Low molecular weight chitosan nanoparticulate system at low N:P ratio for nontoxic polynucleotide delivery. Int J Nanomedicine (2012) 0.87
RNA interference and antiviral therapy. World J Gastroenterol (2007) 0.86
Position-dependent effects of locked nucleic acid (LNA) on DNA sequencing and PCR primers. Nucleic Acids Res (2006) 0.86
NMR structure of a kissing complex formed between the TAR RNA element of HIV-1 and a LNA-modified aptamer. Nucleic Acids Res (2007) 0.86
Targeted delivery of siRNA-generating DNA nanocassettes using multifunctional nanoparticles. Small (2013) 0.86
A novel FRET pair for detection of parallel DNA triplexes by the LightCycler. BMC Biotechnol (2010) 0.86
RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics. Nucleic Acid Ther (2012) 0.86
Cell-specific RNA interference by peptide-inhibited-peptidase-activated siRNAs. J RNAi Gene Silencing (2010) 0.85
siRNA-optimized Modifications for Enhanced In Vivo Activity. Mol Ther Nucleic Acids (2012) 0.85
Phage protein-targeted cancer nanomedicines. FEBS Lett (2013) 0.84
RNA as a stable polymer to build controllable and defined nanostructures for material and biomedical applications. Nano Today (2015) 0.84
Biophysical studies of DNA modified with conformationally constrained nucleotides: comparison of 2'-exo (north) and 3'-exo (south) 'locked' templates. Nucleic Acids Res (2007) 0.84
Effects of local mRNA structure on posttranscriptional gene silencing. Proc Natl Acad Sci U S A (2008) 0.84
Non-Viral Delivery and Therapeutic Application of Small Interfering RNAs. Acta Naturae (2013) 0.83
Position-dependent effects on stability in tricyclo-DNA modified oligonucleotide duplexes. Nucleic Acids Res (2010) 0.82
Dendrimers for siRNA Delivery. Pharmaceuticals (Basel) (2013) 0.82
In vivo efficacy and off-target effects of locked nucleic acid (LNA) and unlocked nucleic acid (UNA) modified siRNA and small internally segmented interfering RNA (sisiRNA) in mice bearing human tumor xenografts. Artif DNA PNA XNA (2010) 0.82
Protection and Systemic Translocation of siRNA Following Oral Administration of Chitosan/siRNA Nanoparticles. Mol Ther Nucleic Acids (2013) 0.82
Epigenetic targets for novel therapies of lung diseases. Pharmacol Ther (2014) 0.81
Development of a 2',4'-BNA/LNA-based siRNA for Dyslipidemia and Assessment of the Effects of Its Chemical Modifications In Vivo. Mol Ther Nucleic Acids (2012) 0.81
MicroRNAs in leukemias: emerging diagnostic tools and therapeutic targets. Curr Drug Targets (2010) 0.81
Pathogenic microRNA's in myeloid malignancies. Front Genet (2014) 0.80
Modified siRNA structure with a single nucleotide bulge overcomes conventional siRNA-mediated off-target silencing. Mol Ther (2011) 0.80
In vivo screening of modified siRNAs for non-specific antiviral effect in a small fish model: number and localization in the strands are important. Nucleic Acids Res (2012) 0.80
A Potential of microRNAs for High-Content Screening. J Nucleic Acids (2011) 0.79
Thermodynamic Control of Small RNA-Mediated Gene Silencing. Front Genet (2012) 0.79
Optimization of an AMBER force field for the artificial nucleic acid, LNA, and benchmarking with NMR of L(CAAU). J Phys Chem B (2014) 0.79
From evolution to revolution: miRNAs as pharmacological targets for modulating cholesterol efflux and reverse cholesterol transport. Pharmacol Res (2013) 0.78
Tracking in vitro and in vivo siRNA electrotransfer in tumor cells. J RNAi Gene Silencing (2008) 0.78
Chemical synthesis of LNA-2-thiouridine and its influence on stability and selectivity of oligonucleotide binding to RNA. Biochemistry (2009) 0.78
The highly conserved 5' untranslated region as an effective target towards the inhibition of Enterovirus 71 replication by unmodified and appropriate 2'-modified siRNAs. J Biomed Sci (2012) 0.78
Fighting against kidney diseases with small interfering RNA: opportunities and challenges. J Transl Med (2015) 0.78
Crystallization and preliminary X-ray study of the D-altritol oligonucleotide GTGTACAC. Acta Crystallogr Sect F Struct Biol Cryst Commun (2010) 0.78
Short-interference RNAs: becoming medicines. EXCLI J (2015) 0.78
siRNAmod: A database of experimentally validated chemically modified siRNAs. Sci Rep (2016) 0.78
The Advancement of the Emerging Field of RNA Nanotechnology. ACS Nano (2017) 0.77
Sub-cellular temporal and spatial distribution of electrotransferred LNA/DNA oligomer. J RNAi Gene Silencing (2013) 0.77
Improving gene silencing of siRNAs via tricyclo-DNA modification. Artif DNA PNA XNA (2010) 0.77
Disease-causing allele-specific silencing by RNA interference. Pharmaceuticals (Basel) (2013) 0.76
Activation of dendritic cells by the novel Toll-like receptor 3 agonist RGC100. Clin Dev Immunol (2013) 0.76
MiR-17-5p impairs trafficking of H-ERG K+ channel protein by targeting multiple er stress-related chaperones during chronic oxidative stress. PLoS One (2013) 0.76
Preparation of novel curdlan nanoparticles for intracellular siRNA delivery. Carbohydr Polym (2014) 0.76
Branched RNA: A New Architecture for RNA Interference. J Nucleic Acids (2011) 0.75
MiR-146a/b: a family with shared seeds and different roots. Physiol Genomics (2017) 0.75
DNA and RNA derivatives to optimize distribution and delivery. Adv Drug Deliv Rev (2015) 0.75
A new design of a lentiviral shRNA vector with inducible co-expression of ARGONAUTE 2 for enhancing gene silencing efficiency. Cell Biosci (2015) 0.75
Immunological research using RNA interference technology. Immunology (2007) 0.75
Targeted therapies through microRNAs: pulp or fiction? Ther Adv Hematol (2012) 0.75
MicroRNA-9 downregulates the ANO1 chloride channel and contributes to cystic fibrosis lung pathology. Nat Commun (2017) 0.75
RNAi therapy to the wall of arteries and veins: anatomical, physiologic, and pharmacological considerations. J Transl Med (2017) 0.75
RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials. Life Sci (2017) 0.75
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 72.56
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 57.23
RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev (2001) 26.16
Asymmetry in the assembly of the RNAi enzyme complex. Cell (2003) 22.18
RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell (2000) 20.32
A species of small antisense RNA in posttranscriptional gene silencing in plants. Science (1999) 19.34
Functional siRNAs and miRNAs exhibit strand bias. Cell (2003) 19.15
Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol (2003) 16.63
Rational siRNA design for RNA interference. Nat Biotechnol (2004) 14.16
Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J (2001) 12.88
ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell (2001) 10.20
Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol (2003) 7.38
siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov (2004) 4.73
Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res (2003) 3.85
RNAi in human cells: basic structural and functional features of small interfering RNA. Mol Cell (2002) 3.81
Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev (2003) 3.46
Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res (2003) 3.39
Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. Chem Biol (2001) 3.26
Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci U S A (2000) 3.04
RNA interference in mammalian cells by chemically-modified RNA. Biochemistry (2003) 2.62
Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res (2002) 2.58
Structural studies of LNA:RNA duplexes by NMR: conformations and implications for RNase H activity. Chemistry (2000) 1.72
The use of TaqMan RT-PCR assays for semiquantitative analysis of gene expression in CNS tissues and disease models. J Neurosci Methods (2000) 1.70
Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design. Nucleic Acids Res (2002) 1.52
Design and characterization of decoy oligonucleotides containing locked nucleic acids. Nucleic Acids Res (2002) 1.40
Effective small interfering RNAs and phosphorothioate antisense DNAs have different preferences for target sites in the luciferase mRNAs. Biochem Biophys Res Commun (2003) 1.06
Characterization of RNA interference in rat PC12 cells: requirement of GERp95. Biochem Biophys Res Commun (2004) 0.85
Genome-wide analysis of mammalian promoter architecture and evolution. Nat Genet (2006) 17.19
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science (2009) 10.30
The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. Nat Genet (2009) 6.02
Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat Med (2008) 5.62
Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet (2011) 4.81
Myogenic gene expression signature establishes that brown and white adipocytes originate from distinct cell lineages. Proc Natl Acad Sci U S A (2007) 4.69
Regulatory roles of natural antisense transcripts. Nat Rev Mol Cell Biol (2009) 4.48
Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci U S A (2002) 4.20
Complex Loci in human and mouse genomes. PLoS Genet (2006) 3.74
The reality of pervasive transcription. PLoS Biol (2011) 3.41
Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nat Biotechnol (2012) 3.07
RNAdb--a comprehensive mammalian noncoding RNA database. Nucleic Acids Res (2005) 2.84
Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY). J Acquir Immune Defic Syndr (2011) 2.75
Using molecular classification to predict gains in maximal aerobic capacity following endurance exercise training in humans. J Appl Physiol (1985) (2010) 2.74
Striatal microRNA controls cocaine intake through CREB signalling. Nature (2010) 2.56
DNA vaccines: progress and challenges. J Immunol (2005) 2.34
A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites. Nucleic Acids Res (2005) 2.27
Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res (2009) 2.22
Hypoxia-independent angiogenesis in adipose tissues during cold acclimation. Cell Metab (2009) 2.11
Evidence for natural antisense transcript-mediated inhibition of microRNA function. Genome Biol (2010) 2.08
MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction. Proc Natl Acad Sci U S A (2009) 2.00
Considerations when using the significance analysis of microarrays (SAM) algorithm. BMC Bioinformatics (2005) 1.89
Human muscle gene expression responses to endurance training provide a novel perspective on Duchenne muscular dystrophy. FASEB J (2005) 1.85
A small molecule enhances RNA interference and promotes microRNA processing. Nat Biotechnol (2008) 1.80
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis (2008) 1.77
Amygdala-dependent fear is regulated by Oprl1 in mice and humans with PTSD. Sci Transl Med (2013) 1.74
Genomic structure of the human mitochondrial chaperonin genes: HSP60 and HSP10 are localised head to head on chromosome 2 separated by a bidirectional promoter. Hum Genet (2002) 1.69
Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res (2010) 1.67
Integration of microRNA changes in vivo identifies novel molecular features of muscle insulin resistance in type 2 diabetes. Genome Med (2010) 1.64
Improved and automated prediction of effective siRNA. Biochem Biophys Res Commun (2004) 1.58
A novel RNA transcript with antiapoptotic function is silenced in fragile X syndrome. PLoS One (2008) 1.57
A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum Mutat (2013) 1.53
A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther (2008) 1.49
MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function. Proc Natl Acad Sci U S A (2012) 1.49
Pseudo-messenger RNA: phantoms of the transcriptome. PLoS Genet (2006) 1.46
Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS One (2009) 1.46
Regulation of chromatin structure by long noncoding RNAs: focus on natural antisense transcripts. Trends Genet (2012) 1.46
Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice. Mol Ther (2006) 1.42
Single nucleotide polymorphisms in the proximal promoter region of the adiponectin (APM1) gene are associated with type 2 diabetes in Swedish caucasians. Diabetes (2004) 1.41
Detection of pancreatic cancer using antibody microarray-based serum protein profiling. Proteomics (2008) 1.38
Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine (2011) 1.37
An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples. FEBS J (2010) 1.36
MicroRNA dysregulation in psychiatric disease. Brain Res (2010) 1.34
DNA vaccines: recent developments and future possibilities. Hum Gene Ther (2006) 1.33
Gene-based vaccines: recent technical and clinical advances. Trends Mol Med (2006) 1.32
Enhanced gene delivery and siRNA silencing by gold nanoparticles coated with charge-reversal polyelectrolyte. ACS Nano (2010) 1.29
Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur J Immunol (2010) 1.27
Apoptosis resistance downstream of eIF4E: posttranscriptional activation of an anti-apoptotic transcript carrying a consensus hairpin structure. Nucleic Acids Res (2006) 1.27
Noncoding RNAs: couplers of analog and digital information in nervous system function? Trends Neurosci (2007) 1.27
Intronic RNAs constitute the major fraction of the non-coding RNA in mammalian cells. BMC Genomics (2012) 1.26
PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Ther (2011) 1.23
RNA interference is not involved in natural antisense mediated regulation of gene expression in mammals. Genome Biol (2006) 1.21
Profiling of mismatch discrimination in RNAi enabled rational design of allele-specific siRNAs. Nucleic Acids Res (2009) 1.21
MALAT-1 interacts with hnRNP C in cell cycle regulation. FEBS Lett (2013) 1.19
A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One (2010) 1.19
Altered regulation of the PINK1 locus: a link between type 2 diabetes and neurodegeneration? FASEB J (2007) 1.19
Expression profiling following local muscle inactivity in humans provides new perspective on diabetes-related genes. Genomics (2005) 1.18
Vaccine delivery methods using viral vectors. Mol Pharm (2007) 1.17
microRNAs in CNS disorders. Neuromolecular Med (2009) 1.17
Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. Mol Ther (2011) 1.16
An endogenous TNF-alpha antagonist induced by splice-switching oligonucleotides reduces inflammation in hepatitis and arthritis mouse models. Mol Ther (2008) 1.15
SPC3042: a proapoptotic survivin inhibitor. Mol Cancer Ther (2008) 1.15
Analysis of siRNA specificity on targets with double-nucleotide mismatches. Nucleic Acids Res (2008) 1.14
Validating siRNA using a reporter made from synthetic DNA oligonucleotides. Biochem Biophys Res Commun (2004) 1.14
NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients. Viral Immunol (2011) 1.13
Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies. Gene Ther (2004) 1.13
A locked nucleic acid oligonucleotide targeting microRNA 122 is well-tolerated in cynomolgus monkeys. Nucleic Acid Ther (2012) 1.12
Therapeutic potential of neuropeptide Y (NPY) receptor ligands. EMBO Mol Med (2010) 1.12
A nonsense mutation (428G-->A) in the fucosyltransferase FUT2 gene affects the progression of HIV-1 infection. AIDS (2006) 1.11
Exogenous IFN-β has antiviral and anti-inflammatory properties in primary bronchial epithelial cells from asthmatic subjects exposed to rhinovirus. J Allergy Clin Immunol (2011) 1.10
Small GTP-binding protein Rac is an essential mediator of vascular endothelial growth factor-induced endothelial fenestrations and vascular permeability. Circulation (2003) 1.10
NotI subtraction and NotI-specific microarrays to detect copy number and methylation changes in whole genomes. Proc Natl Acad Sci U S A (2002) 1.10
Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA. Nucleic Acids Res (2003) 1.10
The human PINK1 locus is regulated in vivo by a non-coding natural antisense RNA during modulation of mitochondrial function. BMC Genomics (2007) 1.10
Personalized medicine in psychiatry: problems and promises. BMC Med (2013) 1.09
Activity-induced and developmental downregulation of the Nogo receptor. Cell Tissue Res (2003) 1.07
Kinetics of senescence-associated changes of gene expression in an epithelial, temperature-sensitive SV40 large T antigen model. Cancer Res (2004) 1.07
Identification of functional SNPs in the 5-prime flanking sequences of human genes. BMC Genomics (2005) 1.07
Effective small interfering RNAs and phosphorothioate antisense DNAs have different preferences for target sites in the luciferase mRNAs. Biochem Biophys Res Commun (2003) 1.06
A new approach to genome mapping and sequencing: slalom libraries. Nucleic Acids Res (2002) 1.05
Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine (2009) 1.05